Publication

Second-Generation ALK Inhibitors: Filling the Non "MET" Gap

Downloadable Content

Persistent URL
Last modified
  • 05/15/2025
Type of Material
Authors
    Suresh Ramalingam, Emory UniversityFadlo Khuri, Emory University
Language
  • English
Date
  • 2014-06-01
Publisher
  • American Association for Cancer Research
Publication Version
Copyright Statement
  • © 2014 American Association for Cancer Research.
Final Published Version (URL)
Title of Journal or Parent Work
ISSN
  • 2159-8274
Volume
  • 4
Issue
  • 6
Start Page
  • 634
End Page
  • 636
Abstract
  • Ceritinib and other second-generation inhibitors have demonstrated promising anticancer activity in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC). Specifically, they can overcome resistance due to certain gatekeeper mutations acquired following crizotinib exposure. These agents now provide new options for the management of ALK-positive NSCLC.
Author Notes
  • Corresponding Author: Fadlo R. Khuri, Department of Hematology and Medical Oncology, Emory University School of Medicine, 1365 Clifton Road NE, Atlanta, GA 30322. Phone: 404-778-4250; Fax: 404-778-1267; fkhuri@emory.edu
Keywords
Research Categories
  • Health Sciences, Oncology

Tools

Relations

In Collection:

Items

Thumbnail Title File Description Date Uploaded Visibility Actions
file details Publication File - v0x1s.pdf Primary Content 2025-04-04 Public Download